India, March 10 -- Shares of Mineralys Therapeutics, Inc. (MLYS) surged nearly 65% on Monday morning after the clinical-stage biopharmaceutical company announced positive topline results from Launch-HTN and Advance-HTN pivotal trials of Lorundrostat for the treatment of uncontrolled or resistant hypertension.
MLYS is currently trading at $17.31, up $6.79 or 64.70%, on the Nasdaq. The stock opened its trading at $14.13 after closing Friday at $10.52. The stock has traded between $8.24 and $15.64 in the past 52-week period.
The company announced positive topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uH...